Full Range of Trials for the Whole Family
Welcome to our Ongoing Trials
Seeking answers to unanswered questions about your health? Look no further.
Delve into the realm of clinical trials below, where you can participate in studies that hold the potential to unlock improved quality of life.
The RD.06.SPR.201593 Trial
An Open-label Drug-Drug Interaction Study to Assess the Effects of Nemolizumab on Cytochrome P450 Substrates in Subjects with Moderate-to-Severe Atopic Dermatitis
ABOUT THE GALDERMA CLINICAL STUDY IN ATOPIC DERMATITIS
Galderma is conducting a clinical study in patients with atopic dermatitis (AD), also called eczema. The objective of this clinical study is to determine if there are pharmacologic interactions between some commonly used medications and an investigational medication called nemolizumab in patients with moderate-to-severe AD (this type of study is called a drug interaction study).
Nemolizumab is currently being developed by Galderma as a potential treatment for AD.
The Galderma drug interaction study (EUDRA CT 2020-000229-24) has been reviewed and authorized by the FDA.
Take the short pre-screener to see if you may qualify!
The FREEDOM-3 Trial
A Phase 2 clinical trial being conducted in patients suffering from diffuse cutaneous systemic sclerosis.
ABOUT THE TALARIS FREEDOM-3 tRIAL
The purpose of this multicenter, single-arm study is to evaluate the safety and tolerability and explore the efficacy of FCR001 cell therapy in adults with rapidly progressive dcSSc at risk for organ failure. It consists of 2 years of treatment and 3 years of follow-up, with the primary analysis performed at 24 months.
FCR001 is a cell therapy product that is administered by intravenous (IV) infusion, following nonmyeloablative (NMA) conditioning. It consists of mobilized peripheral blood cells, facilitating cells, and αβ T cells. This therapy is designed to induce donor-specific tolerance by establishing sustained chimerism and to protect against graft versus host disease (GvHD), the major impediment for advancing allogeneic hematopoietic stem cell therapy (HSCT) as a potential therapy in patients.
Take the short pre-screener to see if you may qualify!
The Realize Trial
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Trial of CVL-865 as Adjunctive Therapy in Adults with Drug-Resistant Focal Onset Seizures (REALIZE Trial)
ABOUT THE REALIZE TRIAL
Cerevel is conducting a clinical trial (the REALIZE trial) to determine effectiveness of the investigational medication darigabat (also called CVL-865) as a treatment option for people with Epilepsy who experience focal onset seizures (also called partial seizures). The REALIZE trial will assess whether darigabat decreases the number of seizures in patients with a diagnosis of epilepsy focal onset seizures that are not responsive to currently available treatments.
The investigational medication darigabat is being developed by Cerevel as a potential treatment for epilepsy with focal onset seizures that are not responsive to treatment.
The Cerevel study has been reviewed and authorized by the FDA and is being conducted in the United States, Europe and Australia. For more information, please take a look at our Additional Information section below, visit https://clinicaltrials.gov/ct2/show/NCT04244175 or https://www.realizestudy.com.
Take the short pre-screener to see if you may qualify!
Minor Surgery
Lorem ipsum dolor sit amet consectet
Lorem ipsum dolor sit amet, consectet adipiscing elit,sed do eiusm por incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis
Mollit natoque consequat massa quis